Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

This study is testing a combination of three treatments — an anti-PD1 immunotherapy, nimotuzumab (a drug targeting a growth protein on cancer cells), and capecitabine (an oral chemotherapy) — for people with nasopharyngeal carcinoma (a cancer of the back of the nasal passage) that has come back or spread despite prior platinum-based chemotherapy. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed recurrent or metastatic nasopharyngeal carcinoma - You have already received platinum-based chemotherapy and your cancer progressed - You have at least one measurable tumor on imaging - You are in good general health (ECOG score 0 or 1) - Your expected survival is at least 3 months - Your blood counts, liver, kidney, and other organ functions meet minimum requirements **You may NOT be eligible if...** - You have a known severe allergy to any of the study drugs - You have active autoimmune disease or chronic steroid use - You have uncontrolled brain metastases - You are pregnant or breastfeeding - You have significant heart, lung, or psychiatric conditions Talk to your doctor to see if this trial is right for you.